B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

By J. Kochenderfer, M. Dudley, S. Feldman, W. Wilson, D. Spaner, I. Maric, M. Stetler-Stevenson, G. Phan, M. Hughes, R. Sherry and 8 more. Blood, 2012

1,404 citations recorded by the source corpus.

Subfields: Oncology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo (2015, neutral): “As a consequence, CAR-T-cell products prepared from PBMC contain divergent proportions of CD8 + and CD4 + T-cell subsets, and this heterogeneity could contribute to the differences in efficacy and toxicity observed in clinical trials 3,5,6,10 .”
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses (2018, neutral): “Despite these encouraging results, safety and efficacy continue to be major hurdles that hinder CAR T cell therapy development (Brentjens et al., 2013; Kochenderfer et al., 2012; Morgan et al., 2010; Scholler et al., 2012).”
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. (2013, background): “Early clinical results have demonstrated impressive antitumor effects in patients with leukemia (6-10), although the ideal CAR design with respect to structural and signaling features remains unclear and has been the topic of intense inquiry.”